Biopharmaceuticals - Quality Development and Documentation

Get an understanding of the quality issues specific to biopharmaceuticals (module 10)

Date icon

25 - 27 Nov 2024

or

1 - 3 Dec 2025

Attendance icon

On location

Language icon

English

Price icon
22,273 DKK ex VAT

(app. 2,995 EUR ex VAT)

Summary

This three day course will teach you about the scientific background of biologics and biotechnological products as well as which regulatory requirements you need to fulfil in order to obtain approval for these types of medicinal products. 
You will get an understanding of the quality issues specific to biopharmaceuticals. As process changes are inevitable during the development of a biological/biotechnological product, this course will teach you about the implications of changes in the production process and elaborate on the concept of comparability. 

You will also learn how to prepare regulatory (CMC)  and quality strategies as well as how to ensure that you are compliant with regulatory requirements throughout the clinical development and post-approval processes. Our discussions on CMC/Quality strategies will include both FDA and EU aspects as well as FDA and EU regulatory procedures for approval.


Other course participants say

"The course has provided me with a very good overview and understanding on the regulatory CMC requirements for development of biologics." 

Helene Mortensen, Principal Scientist, Biopharmaceutical Product Development, CMC, LEO Pharma A/S


“Good introductory course to regulatory processes.“ 

Birgitte Schousboe, QA Manager, Symphogen A/S



    Keywords

    • Biopharmaceuticals
    • Chemistry, Manufacturing and Controls (CMC)
    • Regulatory CMC strategies
    • Quality Sections for IND/CTA and BLA/NDA /MAA
    • Product Comparability
    • Biosimilars
    • Product Characterization and Specification
    • Quality Regulatory Compliance Strategy
    • EU and FDA Regulatory Procedures for Biotech Products

    Please note: 

    As this module is a mandatory module in the Master of Medicines Regulatory Affairs at the University of Copenhagen you will apply via the joint Atrium and University of Copenhagen application form. This means that you will be enrolled at both Atrium and the University of Copenhagen and that your data will be registered at both institutions. If you are not enrolled as a master student, you will be registered as a single course student at the University of Copenhagen.

    Course fee includes examination. By default you will pay the full amount to the University of Copenhagen regardless of you taking the exam or not. If you decide not to take the exam, you can apply for a refund of the exam fee at Atrium by contacting Atrium - please see contact details below. You must apply for a refund no later than two weeks after completion of the course.


    Save information for later
    Read more

    Course leader & lecturers

    • Heidi Smed Christensen
      Course leader
      Senior Director, Regulatory Affairs
      Genmab A/S
    • Sandra Auguste-Bowler
      Course leader
      Principal regulatory specialist
      Novo Nordisk A/S
    • Sarah Gilgunn
      Lecturer
      Ph.d., Pharmaceutical Assessor (Biologicals), Human Authorisation and Registration
      Health Products Regulatory Authority
    See all

    Watch the video

    Is this course for you?

    This course is for you if you work as a regulatory affairs specialist, employed in the industry, a regulatory agency, or a consulting firm.

    You must have a minimum of 2 years relevant job experience.

    What you will learn

    1. The basic principles of manufacturing biopharmaceuticals — from the recombinant starting material to the final product
    2. How to evaluate and organize information provided by CMC/quality stakeholders during product development and post-approval
    3. How to prepare regulatory CMC/quality strategies considering both FDA and EU aspects throughout clinical development and how to evaluate relevant regulations and guidelines for biopharmaceuticals
    4. How to use best practice in product characterization and how to set the release and stability specifications of a biopharmaceutical

    What your company will get

    1. A regulatory professional who understands the basic principles of manufacturing biopharmaceuticals
    2. A regulatory affairs professional who is able to evaluate and organize the information and documentation provided by CMC/Quality stakeholders, challenge it and ask the right questions
    3. A regulatory affairs professional who is able to prepare regulatory CMC/Quality strategies considering both FDA and EU aspects

    Course calendar

    Choose your starting date
    Starting 25 Nov 2024
    Starting 1 Dec 2025
    25 Nov 2024 8:15-17:45
    Day 1
    • Why do regulatory agencies treat biopharmaceuticals differently than chemical pharmaceuticals?
    • CMC/quality sections for IND/CTA and BLA/NDA/MAA in CTD
    • Generation of the recombinant construct, Cell Banks, and Expression System
    • Purification and process validation
    • Group work
    26 Nov 2024 8:15-17:20
    Day 2
    • Regulatory expectations for product characterization
    • Demonstrating product comparability during development and post-approval
    • Formulation development and drug product manufacturing
    • Setting a product specification for drug substances and drug product
    • Group work
    27 Nov 2024 8:15-16:30
    Day 3
    • Stability studies for drug substance and drug product
    • Biosimilars
    • EU regulatory procedures for biotech products
    • Key elements necessary for a complete quality regulatory compliance strategy
    • FDA regulatory procedures for biotech products
    • Group work
    Practical information

    Registration

    Registration deadline
    27 Oct 2024
    Atrium
    Lersø Parkallé 101
    2100 København Ø
    Register
    25 - 27 Nov
    1 Dec 2025 8:15-17:45
    Day 1
    • Why do regulatory agencies treat biopharmaceuticals differently than chemical pharmaceuticals?
    • CMC/quality sections for IND/CTA and BLA/NDA/MAA in CTD
    • Generation of the recombinant construct, Cell Banks, and Expression System
    • Purification and process validation
    • Group work
    2 Dec 2025 8:15-17:20
    Day 2
    • Regulatory expectations for product characterization
    • Demonstrating product comparability during development and post-approval
    • Formulation development and drug product manufacturing
    • Setting a product specification for drug substances and drug product
    • Group work
    3 Dec 2025 8:15-16:30
    Day 3
    • Stability studies for drug substance and drug product
    • Biosimilars
    • EU regulatory procedures for biotech products
    • Key elements necessary for a complete quality regulatory compliance strategy
    • FDA regulatory procedures for biotech products
    • Group work
    Practical information

    Registration

    Registration deadline
    3 Nov 2025
    Atrium
    Lersø Parkallé 101
    2100 København Ø
    Register
    1 - 3 Dec
    Sometimes things change. This is the expected programme.

    Course information

    Literature

    Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

    Please familiarize yourself with the mandatory readings before starting the course.

    The mandatory readings are also part of the examination syllabus. 

    Prerequisites

    To enroll in this course, you must have a relevant educational background at bachelor level and, as a minimum, two years of experience in regulatory affairs, or other equivalent qualifications. We consider all applications upon registration.

    If you do not fulfill the requirements, you can still apply for the course if you have experience in the pharmaceutical/biological area that would allow you to benefit from the training and enable you to participate actively during the module. Up to 20% of the positions on our course are filled by applicants who have no or limited experience in regulatory affairs. We consider applicants on a case-by-case basis.

    Examination

    The exam is usually held 4-6 weeks after the course.

    It is a digital exam in the University of Copenhagen’s digital exam system.

    This course is a part of a diploma

    Master of Medicines Regulatory Affairs (MRA)

    Are you a Regulatory Affairs professional and are you concerned with your ongoing learning and development? Consider these courses, offered in together with University of Copenhagen. Explore the Master of Medicines Regulatory Affairs (MRA).

    Read more
    Diploma in Regulatory Affairs

    The regulatory affairs diploma gives you an understanding of the entire regulatory affairs platform of the medicinal lifecycle. All courses have been designed in collaboration with highly acclaimed experts that are on our regulatory affairs Advisory Board.

    Read more

    Course leaders

    Heidi Smed Christensen
    Senior Director, Regulatory Affairs
    Genmab A/S
    Sandra Auguste-Bowler
    Principal regulatory specialist
    Novo Nordisk A/S

    Lecturer

    Sarah Gilgunn
    Ph.d., Pharmaceutical Assessor (Biologicals), Human Authorisation and Registration
    Health Products Regulatory Authority

    You may also be interested in these courses

    Want to know more or need help?

    Contact Educational Programme Leader Lone Rex at +45 20 62 11 46

    Send me a message